Received Jun 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
| TDAP | TDAP (ADACEL) | SANOFI PASTEUR | UNK | U8122AA | IM / RA |
administration of adacel outside of the recommended interval with no reported adverse event; This non-serious case was reported by a other health professional via other manufacturer and described the occurrence of interchange of vaccine products in a 52-year-old patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. Co-suspect products included Diphtheria vaccine toxoid, Pertussis vaccine acellular 5-component, Tetanus vaccine toxoid (Adacel) (batch number U8122AA, expiry date 30-APR-2026) for prophylaxis. On 06-MAR-2025, the patient received Boostrix. On 29-APR-2025, the patient received Adacel (intramuscular use, right arm) .5 ml. On an unknown date, an unknown time after receiving Boostrix, the patient experienced interchange of vaccine products (Verbatim: administration of adacel outside of the recommended interval with no reported adverse event). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-JUN-2025 The reporter reported that, the patient received an unknown dose (0.5 ml) of adacel via intramuscular route in the right arm for immunization and then, the patient received an unknown dose of Boostrix vaccine which led to interchange of vaccine products.